Navigation Links
Novel live reporting system to track cells

New findings show an iron storage molecule in the cell can serve as an advanced tool for mapping gene expression. Future gene therapy may use a technique in which non-invasive magnetic resonance imaging (MRI) is used to track this molecule. The results of this research, conducted by Prof. Michal Neeman of the Weizmann Institute's Biological Regulation Department, were published in the research journal Neoplasia.

Neeman, together with Dr. Batya Cohen of the Institute's Molecular Genetics Department, developed the capacity of the iron-bearing ferritin molecule to serve as a sort of gene "spy" by making genetic modifications to cells. This approach rendered ferritin sensitive to tetracycline (TET), a common antibiotic, so that when TET is present, the ferritin is "off" and when TET is absent, ferritin is "on." Tumor cells with modified ferritin were inserted into living mice and then tracked with MRI. The researchers hampered the expression of ferritin in the inserted cells through the administration of TET. When they stopped the TET, the "switch" turned on, triggering ferritin molecules to increase their numbers, thereby causing an increase in iron uptake within the tumor cells. The contrast between the iron content in these and in the normal surrounding cells showed up in the MRI (which is sensitive to magnetic particles such as iron), effectively identifying the genetically modified cells.

This method grew out of a joint vision that originated 10 years ago in collaboration with the late Dr. Yoav Citri. Ferritin's advantage is that it is visible in MRI without the need for an additional contrast material. This technique has far-reaching implications for monitoring the progress of gene therapy, such as that used to reactivate the body's production of insulin in the treatment of diabetes, because the genes can be "tagged" prior to injection. Therapeutic genes can then be tracked by MRI to ensure the target is reached and the desired activations occur. Pr of. Neeman: "The use of ferritin as a reporter gene would be particularly beneficial in those cases where administration of contrast material is compromised by barriers, including embryonic development and the central nervous system."


Source:American Committee for the Weizmann Institute of Science

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. Discovery Could Lead To Novel Approaches In HIV Treatment
7. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
8. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
9. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
10. Field of beams - Novel system uses polarized light pulses to reveal crop health
11. Novel compounds show promise as safer, more potent insecticides
Post Your Comments:

(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)...   Growing need for low-cost, easy to ... paving the way for use of biochemical sensors ... in clinical, agricultural, environmental, food and defense applications. ... medical applications, however, their adoption is increasing in ... emphasis on improving product quality and growing need ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... FAR HILLS, N.J. (PRWEB) , ... November 24, 2015 , ... ... University, as the recipient of the 2016 USGA Green Section Award. Presented annually since ... of golf through his or her work with turfgrass. , Clarke, of ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
Breaking Biology Technology: